Marker Therapeutics (MRKR) Research & Development (2010 - 2026)

Marker Therapeutics (MRKR) has 17 years of Research & Development data on file, last reported at $2.8 million in Q1 2026.

• Research & Development for Q1 2026 came in at $2.8 million, down 9.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.5 million (down 17.98% YoY), and the FY2025 annual result was $11.8 million, down 12.39% from the prior year.
• Research & Development advanced to $2.8 million in Q1 2026 per MRKR's latest filing, from $2.1 million in the prior quarter.
• Over five years, Research & Development peaked at $7.0 million in Q1 2022 and troughed at $2.0 million in Q3 2023.
• A 5-year average of $3.2 million and a median of $2.8 million in 2026 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2024: Research & Development plunged 72.78% in 2022, then surged 94.33% in 2024.
• A 5-year view of Research & Development shows it stood at $2.2 million in 2022, then advanced by 19.93% to $2.6 million in 2023, then surged by 94.33% to $5.1 million in 2024, then slumped by 57.91% to $2.1 million in 2025, then jumped by 32.79% to $2.8 million in 2026.
• Business Quant data shows MRKR's Research & Development at $2.8 million in Q1 2026, $2.1 million in Q4 2025, and $2.3 million in Q3 2025.